Work

Lebrikizumab for adolescent atopic dermatitis: 24-week real-world outcomes from the Czech BIOREP registry

Year: 2026

Type: article

Study design: Observational Study

Abstract: Lebrikizumab, a novel anti-interleukin-13 antibody for atopic dermatitis (AD), has demonstrated efficacy and safety in clinical trials in adults and adolescents; however, real-world evidence in adolescents remains limited.1,2 This analysis evaluates the effectiveness and safety of lebrikizumab over 24 weeks in adolescents enrolled in the Czech BIOREP registry.

Source: JAAD International

DOI: 10.1016/j.jdin.2026.01.009

Authors: Filip Rob, Blanka Pinková, Petra Gkalpakioti, Jiřina Bartoňová, Jiří Horažďovský, Jan Říčař, Jana Třešňák Hercogová, Kristýna Sokolová

Institutions: Charles University, Fakultní nemocnice Bulovka, Masaryk University, University Hospital Kralovske Vinohrady, Nemocnice České Budějovice

Language: English

Topic: Dermatology and Skin Diseases

Subfield: Dermatology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,575

Funders: Eli Lilly and Company, Pfizer, Sanofi, Univerzita Karlova v Praze, Masarykova Univerzita

OpenAlex ID: W7126418878

FWCI: 5.358

Cites: 3

Cited by: 1

Related to: 10